Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yifenidone - HEC Pharm

Next Previous
Drug Profile

Yifenidone - HEC Pharm

Alternative Names: [14C]-HEC585; HEC00000585; HEC585

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HEC Pharm
  • Developer HEC Pharm; Sunshine Lake Pharma
  • Class Antifibrotics; Hepatoprotectants; Pyrimidinones
  • Mechanism of Action Transforming growth factor alpha inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • No development reported Hepatic fibrosis

Most Recent Events

  • 24 Jul 2025 Sunshine Lake Pharma plans phase-III trial for Idiopathic pulmonary fibrosis (In adults, In the elderly) in October 2025 (PO, Tablet) (NCT07082842),
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in USA (PO, Capsule)
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top